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Background. Cryptococcal meningitis (CM) causes 10%–20% of HIV-related deaths in Africa. Due to limited access to lipo-
somal amphotericin and flucytosine, most African treatment guidelines recommend amphotericin B deoxycholate (AmB-d) plus 
high-dose fluconazole; outcomes with this treatment regimen in routine care settings have not been well described.
Methods. Electronic national death registry data and computerized medical records were used to retrospectively collect demo-
graphic, laboratory, and 1-year outcome data from all patients with CM between 2012 and 2014 at Botswana’s main referral hospital, 
when recommended treatment for CM was AmB-d 1 mg/kg/d plus fluconazole 800 mg/d for 14 days. Cumulative survival was esti-
mated at 2 weeks, 10 weeks, and 1 year.
Results. There were 283 episodes of CM among 236 individuals; 69% (163/236) were male, and the median age was 36 years. 
All patients were HIV-infected, with a median CD4 count of 39 cells/mm3. Two hundred fifteen person-years of follow-up data were 
captured for the 236 CM patients. Complete outcome data were available for 233 patients (99%) at 2 weeks, 224 patients (95%) at 10 
weeks, and 219 patients (93%) at 1 year. Cumulative mortality was 26% (95% confidence interval [CI], 20%–32%) at 2 weeks, 50% 
(95% CI, 43%–57%) at 10 weeks, and 65% (95% CI, 58%–71%) at 1 year.
Conclusions. Mortality rates following HIV-associated CM treated with AmB-d and fluconazole in a routine health care setting 
in Botswana were very high. The findings highlight the inadequacies of current antifungal treatments for HIV-associated CM and 
underscore the difficulties of administering and monitoring intravenous amphotericin B deoxycholate therapy in resource-poor 
settings.
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HIV-associated cryptococcal meningitis (CM) causes an esti-
mated 181 100 deaths per year, 73% of which occur in sub-Saha-
ran Africa (SSA) [1]. Ten-week mortality in developed country 
settings is as low as 10%–15% with amphotericin B deoxycho-
late (AmB-d)–based treatment [2–5]. In contrast, even under 
ideal clinical trial conditions, 10-week mortality with AmB-d-
based therapies in Africa is around 30%–40% [6–8]. As AmB-d 
requires prolonged hospitalization with daily intravenous (IV) 
administration and is associated with hematological, renal, and 
metabolic toxicities [9], many under-resourced settings instead 
rely on oral fluconazole. Fluconazole monotherapy is associated 
with worse fungal clearance and an estimated 70% mortality 
within 3 months [10].
Short- and long-term outcomes with AmB-d under routine 
care settings in SSA are not well described. Several factors are 
important in CM management and may affect outcomes even 
with highly fungicidal AmB-d, including pretreatment hydra-
tion, electrolyte supplementation and regular laboratory mon-
itoring for AmB-d-related toxicities [11], therapeutic lumbar 
punctures for management of intracranial pressure [12], and 
initiation and timing of antiretroviral therapy (ART) [6]. As 
countries in SSA increasingly adopt AmB-d, as recommended 
in international guidelines [13, 14], usually given with high-
dose fluconazole due to lack of access to flucytosine in Africa 
[15], a better understanding of outcomes in routine hospital set-
tings is needed to accurately characterize morbidity and mor-
tality from cryptococcal disease and to improve management.
Botswana, a middle-income country in Southern Africa 
with a 25% adult HIV prevalence and high incidence of CM 
[16, 17], has been using AmB-d for over a decade [18]. National 
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treatment guidelines recommend 14-day treatment with AmB 
deoxycholate 1  mg/kg/d and fluconazole 800  mg/d, followed 
by fluconazole maintenance [19]. Utilizing Botswana’s robust 
electronic national death registry and computerized medical 
records systems, we collected clinical, laboratory, and compre-
hensive 1-year outcome data of patients with microbiologically 
confirmed CM between 2012 and 2014 at the country’s major 
referral hospital to assess mortality with amphotericin-based 
therapy under usual care conditions and explore factors associ-
ated with poor outcomes.
METHODS
Participants and Procedures
Data were retrospectively collected on consecutive patients 
admitted to Princess Marina Hospital with laboratory-con-
firmed CM between January 1, 2012, and December 31, 
2014. Princess Marina Hospital is a 530-bed public hospital 
in Gaborone that serves as 1 of 2 national referral centers for 
Botswana, providing free treatment to all citizens. The study 
was conducted in accordance with the ethical standards of 
the Helsinki Declaration (amended in 2008) and approved by 
institutional review boards at the University of Pennsylvania, 
University of Botswana, and Princess Marina Hospital, as well 
as the Botswana Ministry of Health’s Health Research and 
Development Committee. A  waiver of informed consent was 
obtained as we collected routine retrospective data and as indi-
vidual-level patient data were anonymized for the analysis. We 
included all patients who had laboratory-confirmed CM by 
either cerebrospinal fluid (CSF) India ink stain, cryptococcal 
antigen (CrAg) latex agglutination test, or fungal culture, with 
no exclusion criteria. Patients re-admitted with a recurrence 
of CM symptoms and laboratory-confirmed CM at any time 
point after their initial admission were classified as relapse epi-
sodes. During the study period, the recommended treatment 
for CM was amphotericin B deoxycholate 1  mg/kg/d IV plus 
fluconazole 800 mg/d orally for 14 days, followed by standard 
fluconazole consolidation and maintenance therapy. Electrolyte 
supplementation was given at the responsible physician’s dicre-
tion. Antiretroviral therapy (ART) was freely available in the 
hospital and at public sector clinics, with tenofovir, emtricit-
abine, and efavirenz as firstline.
Evaluation and Outcomes
Cases of CM were identified through review of prospectively 
collected laboratory records. Demographic information and 
laboratory results, including blood tests, CSF results, HIV sta-
tus and associated laboratory results, and basic clinical infor-
mation including ART use and admission and discharge dates, 
were then retrospectively obtained for all patients from the elec-
tronic medical records system. More detailed clinical history 
and examination findings, CSF opening pressure recordings, 
and CM treatment details were obtained from detailed review 
of paper hospital records, where available, using a standardized 
data collection form. Time from hospital triage to initiation of 
antifungal therapy, duration and cumulative dosage of antifun-
gal therapies, number of missed drug doses, frequency of toxic-
ity monitoring, and details of management of raised intracranial 
pressure were recorded for each CM episode. Mortality data for 
all patients were collected by linking laboratory records to the 
electronic national death registry at the Botswana Ministry of 
Labour and Home Affairs using unique individual identifiers 
(name, date of birth, and Omang [national identification num-
ber]) at the end of December 2015. Cumulative mortality at 2 
weeks, 10 weeks, and 1 year after hospital admission with CM 
were recorded.
Statistical Analysis
Baseline demographic, clinical, and laboratory variables were 
summarized using descriptive statistics (counts and percent-
ages, medians and interquartile ranges [IQRs]), and proportions 
were compared using χ2 testing. Cumulative survival was esti-
mated at 2 weeks, 10 weeks, and 1 year after initial admission for 
all patients (ie, from the first admission if a patient had multiple 
episodes of CM) and displayed graphically on a Kaplan-Meier 
curve. Sensitivity analyses were performed assuming all miss-
ing patients either survived or died at the point of censoring. 
Cox proportional hazards models were constructed to explore 
factors associated with mortality. Unadjusted and adjusted haz-
ard ratios were estimated for predictors of interest, and P values 
were derived using the likelihood ratio test. Statistical signifi-
cance was defined as a P value ≤.05. Analyses were performed 
using Stata, version 13 (College Station, TX).
RESULTS
During the study period, there were 283 episodes of CM among 
236 individuals (199 patients had a single episode, and 37 
patients had 2 or more episodes a median [IQR] of 133 [23–
614] days apart) (Table 1). The median age (IQR) was 36 (32–
42) years, and 69% (163/236) of patients were male. All patients 
were HIV-infected, with a median baseline CD4 count (IQR) 
of 39 (17–83) cells/mm3. Seventy-five percent (177/236) of 
patients had documentation of HIV infection before their initial 
CM admission, diagnosed a median (IQR) of 14 (2–63) months 
earlier. Of the known HIV-infected individuals with treatment 
data available, 57% (81/141) were taking ART at admission, 
started a median (IQR) of 31 (6–156) weeks before. Baseline 
laboratory data were available for all patients (Table 1). Eighty-
nine percent (210/236) were India ink–positive at first pres-
entation. The median CSF white cell count (IQR) was 10 (0–62) 
cells/µL, with a median lymphocyte predominance (IQR) of 
98% (90%–99%). Paper clinical records were retrieved for 64% 
(180/283) of CM episodes. Headache was the most frequently 
recorded presenting symptom, documented in 86% (n = 154) 
of all CM episodes and present for a median (IQR) of 7 (5–14) 
days before admission. Forty-two percent (n = 74) of individ-
uals had abnormal mental status at presentation (defined as a 
D
ow
nloaded from
 https://academ
ic.oup.com
/ofid/article-abstract/5/11/ofy267/5142727 by London School of H
ygiene & Tropical M
edicine user on 13 D
ecem
ber 2018
Mortality in Cryptococcal Meningitis • OFID • 3
Glasgow Coma Score [GCS] <15). CSF opening pressure (OP) 
was documented in 62% (n = 112) of episodes, with a median 
OP (IQR) of 39 (30–55) cm H2O. Other common documented 
presenting symptoms were vomiting (55%, n = 96) and visual 
disturbances (37%, n = 65). Comorbidities were common, with 
a history of treated tuberculosis (TB) in 27% of cases (n = 48) 
and concurrent TB treatment in 9% (n = 16).
Treatment and Monitoring
All patients were treated with AmB-d (at a dose of approxi-
mately 0.7–1  mg/kg/d) plus fluconazole 800  mg/d during the 
study period. Patient weights were not reliably documented in 
the medical notes, and the majority of patients (81%) received a 
dose of 50 mg/d, equating to a single vial of AmB-d. There was 
a median (IQR) of 2 (1–3) days from presentation to adminis-
tration of the first AmB-d dose (Table 2). Over half of patients 
missed at least 1 dose of AmB-d; 20% missed a single dose, 12% 
missed 2 doses, and 21% missed 3 or more doses. Baseline full 
blood count (FBC) and renal function were available for 91% 
(n = 257) and 87% (n = 245), respectively. Patients had a median 
(IQR) of 1 (0–1) monitoring (ie, post-baseline) FBC and 2 (1–3) 
monitoring renal function and electrolyte tests during admis-
sion. Even with this infrequent monitoring, Division of AIDS 
(DAIDS) [20] Grade 3 anemia (hemoglobin [Hb] < 7.5 g/dL) was 
observed in 46 cases (29% of those tested), and Grade 4 anemia 
(Hb < 6.5g/dL) was observed in 27 cases (17% of those tested). 
Grade 3 creatinine rises (216–400  µmol/L/2.47–4.42  mg/dL) 
were observed in 22 cases (10% of those tested), and Grade 4 
creatinine rises (>400 µmol/L/>4.42 mg/dL) were observed in 3 
cases (1%). Therapeutic lumbar punctures were documented in 
46% (129/283) of cases.
Missed AmB-d doses were more frequent in patients devel-
oping DAIDS Grade 4 anemia during treatment (47% [8/17] of 
whom missed 3 or more doses vs 15% [13/84] of those with-
out; P <  .01) and Grade 3 hypokalemia (44% [7/17] of whom 
missed 3 or more doses vs 17% [20/119] of those without; 
P =  .01), but not in patients developing DAIDS Grade 3 or 4 
renal impairment.
Mortality
Two hundred fifteen person-years of follow-up data were cap-
tured for the 236 CM patients. Complete outcome data were 
available for 233 patients (99%) at 2 weeks, 224 patients (95%) 
at 10 weeks, and 219 patients (93%) at 1 year after initial pres-
entation with CM. Overall mortality was 26% (95% confidence 
interval [CI], 20%–32%) at 2 weeks, 50% (95% CI, 43%–57%) 
at 10 weeks, and 65% (95% CI, 58%–71%) at 1 year (Figure 1). 
In sensitivity analysis, assuming all patients missing outcome 
data were either alive or dead, the point estimates for mortality 
were 25% (60/236) and 27% (63/236), respectively, at 2 weeks; 
47% (112/236) and 53% (124/236), respectively, at 10 weeks; 
and 60% (142/236) and 67% (159/236), respectively, at 1 year 
(Table 2).
Associations With Mortality
Baseline factors significantly associated with 2-week and 
10-week mortality in univariable analysis were abnormal men-
tal status (GCS  <  15), older age (>50  years), anemia (<7.5  g/
dL), raised peripheral white cell count (>10  ×  109/L), renal 
impairment (creatinine >110  µmol/L/>1.24  mg/dL), hypon-
atremia (<125  mmol/L), and low CSF white cell count (<20 
cells/µL) (Table 3A). There was no evidence for lower mortal-
ity in ART-experienced patients (Table 3A, Figure 1B) despite 
ART-experienced patients having significantly higher baseline 
Table 1. Baseline Characteristics
Cryptococcal Meningitis: Patients and Episodes
Total No. of patients 236
Total No. of episodes 283
1 236 (83%)
2 37 (13%)
3 8 (3%)
4 2 (1%)
Variable No. With Data
(of 236 Patients)
Value, Median (IQR) 
Unless Otherwise Stated
Baseline characteristics of patients (restricted to 1st episode of cryptococcal 
meningitis)
Age, y 234 36 (32–42)
Male sex, % (No.) 236 69 (163)
Headache, % (No.)a 155 86 (134)
Vomiting, % (No.)a 151 54 (81)
Visual disturbance, % (No.)a 155 35 (54)
Symptom duration, da 119 7 (5–14)
Glasgow Coma Scale score <15, 
% (No.)a
155 40 (62)
Focal neurology, % (No.)a 154 14 (21)
CSF opening pressure, cm H2O
a 94 38 (28–48)
India ink, % positive (No.) 235 89 (210)
CSF protein, g/dL 194 0.74 (0.47–1.38)
CSF glucose, mmol/L 195 2.3 (1.5–2.9)
CSF white cell count, cells/µL 229 10 (0–62)
CSF lymphocyte, % 105 98 (90–99)
HIV and TB status
Prior diagnosis of HIV, % (No.) 236 75 (177)
Time from HIV diagnosis to 
CM, mo
217 14 (2–63) 
On ART at CM diagnosis, % 
(No.)
181 45 (81)
Time from ART initiation to 
CM, d
181 217 (40–1095)
Baseline CD4 cell count, cells/µL 192 39 (17–82)
Previously treated for TB, % 
(No.)a
152 26 (39)
Current on TB treatment, % 
(No.)a
151 9 (13)
Abbreviations: ART, antiretroviral therapy; CM, cyptococcal meningitis; CSF, cerebrospinal 
fluid; IQR, interquartile range; TB, tuberculosis.
aThese data were derived from paper records. Paper records were retrieved for 64% 
(180/283) of CM episodes, or 66% (156/236) of patients. Note that the results in the table 
are restricted to the first episode only in individuals who had more than 1 episode of CM. 
The overall results of these paper record variables for each episode of CM (ie, including 
both first and relapse episodes) are given in the text.
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CD4 counts (Supplementary Table 1). In multivariable analysis, 
abnormal mental status, older age, raised peripheral white cell 
count, hyponatremia, and low CSF white cell count remained 
independently associated with acute mortality (Table  3B). 
ART status was not associated with 2-week mortality, but 
ART-experienced patients had significantly higher hazards of 
death at 10 weeks and 1 year. Relapse episodes were associated 
with lower rates of India ink positivity, higher CSF white cell 
counts, higher CD4 counts, and lower acute mortality than 
initial episodes (0% vs 26% at 2 weeks and 9% vs 50% at 10 
weeks; P < .01 for both comparisons) (Supplementary Table 2). 
Missing AmB-d doses during induction treatment was associ-
ated with significantly higher mortality at 2 weeks, 10 weeks, 
and 1 year (at 2 weeks: hazard ratio [HR], 3.20; 95% CI, 1.4–7.1; 
at 10 weeks: HR, 2.30; 95% CI, 1.4–3.9; at 1 year: HR, 2.33; 95% 
CI, 1.4–3.8) (Table 3 and Figure 1D). This association remained 
significant in an analysis limited to individuals who did not 
develop DAIDS Grade 3 anemia, hypokalemia, or renal impair-
ment during treatment, that is, the 3 potential dose-limiting 
toxicities leading to AmB-d discontinuation (at 2 weeks: HR, 
7.30; 95% CI, 0.9–60.0; at 10 weeks: HR, 4.55; 95% CI, 1.3–16.3; 
at 1 year: HR, 2.77; 95% CI, 1.1–7.3).
DISCUSSION
Mortality following HIV-associated cryptococcal meningitis in 
a routine health care setting in Botswana was very high, with 
only 35% of patients surviving to 1  year. The comprehensive 
national death registration system in Botswana, combined with 
an electronic medical records system, provided the unique 
opportunity to accurately determine long-term outcomes in a 
large observational cohort of patients treated with amphotericin 
B deoxycholate therapy given with high-dose fluconazole under 
“real-world” routine care conditions in sub-Saharan Africa. 
These poor patient outcomes, in 1 of the better-resourced health 
care systems in Africa with good access to antiretroviral ther-
apy, highlight the inadequacies of current antifungal treatments 
for HIV-associated cryptococcal meningitis. The findings also 
underscore the difficulties faced by busy clinicians in resource-
poor settings in administering and monitoring 14 days of intra-
venous amphotericin B deoxycholate therapy and managing 
the frequent drug-associated toxicities, with the majority of 
patients receiving incomplete treatment courses.
Mortality rates in this cohort of patients with HIV-associated 
cryptococcal meningitis were substantially higher than those 
reported in recent randomized clinical trials (RCTs) from 
low-resource settings [8, 21, 22]. Ten-week mortality in patients 
treated with amphotericin B plus fluconazole in trial settings 
has ranged from 33% to 41% [8, 21, 22], compared with 50% 
(95% CI, 43%–57%) in this routine care cohort. Although some 
of this observed difference may reflect the selection and survival 
bias inherent in clinical trials, where the sickest patients may 
either die before study enrollment or be too unwell to consent to 
study inclusion, it is likely that the more intensive nursing, med-
ical care, and toxicity monitoring in clinical trials leads to more 
Table 2. Treatment and Outcomes
Variable
No. With Data
(of 283 Episodes)
Value, Median (IQR) 
or % (No.)
Duration of admission, d 270 17 (11–22)
Time from admission to 1st 
amphotericin dose, d
159a
0 11 (18)
1 36 (57)
2+ 53 (84)
No. of missed amphotericin 
dosesa,b
159a
0 47 (74)
1–2 32 (51)
3+ 21 (34)
Baseline CSF opening pressure 
recorded
175 64 (112)
No. of therapeutic lumbar 
puncturesc
0 283 54 (154)
1 16 (46)
2 11 (32)
3 8 (23)
4+ 10 (28)
No. of monitoring full blood 
countsc
283 1 (0–1)
Median drop in hemoglobin, 
g/dLc
146 2.0 (1.0–3.4)
Median nadir hemoglobin, g/dLc 161 8.9 (7.3–11.1)
DAIDS Grade 3 anemia, <7.5 g/
dLc
161 29 (46)
DAIDS Grade 4 anemia, <6.5 g/
dLc
161 17 (27)
No. of monitoring electrolyte 
testsc
283 2 (1–2)
Median nadir serum potassium, 
mmol/Lc
222 3.2 (2.8–3.9)
DAIDS Grade 3 hypokalemiac 222 9 (21)
DAIDS Grade 4 hypokalemiac 222 0 (0)
No. of monitoring creatinine 
testsc
283 2 (1–3)
Median peak creatinine, µmol/
Lc
223 105 (73–147)
Median % rise in creatininec 194 53 (9–117)
DAIDS Grade 3 creatinine risec 223 10 (22)
DAIDS Grade 4 creatinine risec 223 1 (3)
Outcomesd
Mortality at 2 wk, % (No.) 233 26 (60)
Mortality at 10 wk, % (No.) 224 50 (112)
Mortality at 1 y, % (No.) 219 65 (142)
Abbreviations: CSF, cerebrospinal fluid; DAIDS, Division of AIDS; IQR, interquartile range.
aThese data were derived from paper records. Paper records were retrieved for 64% 
(180/283) of CM episodes, or 66% (156/236) of patients.
bThe number of missed doses was calculated from the first dose, by subtracting the 
actual number of doses given over 14 days from the recommended 14 doses, or, if the 
patient died before 14 doses, by subtracting the actual number of doses given from the 
number of days a patient was alive and should have received a dose.
cThese data were derived from electronic laboratory records. Note that the number of 
therapeutic lumbar punctures may be underestimated as CSF may not always have been 
sent to the laboratory for analysis, although it is routine hospital practice to do so.
dReported from date of first episode.
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regular drug administration, enhanced management of raised 
intracranial pressure, and earlier recognition and management 
of amphotericin B–related toxicities—all potentially contribut-
ing to improved survival [11, 12, 23, 24]. A large proportion of 
deaths occurred in the early posthospitalization period, empha-
sizing the need for close outpatient monitoring of patients fol-
lowing initial cryptococcal meningitis treatment.
In this routine care cohort, toxicity monitoring was per-
formed less frequently than recommended in World Health 
Organization guidelines [14], with a median of 1 postbase-
line full blood count and 2 postbaseline creatinine and elec-
trolyte tests performed per admission, similar to recent 
laboratory-based surveillance data from Gauteng Province, 
South Africa, in which once-weekly laboratory monitoring of 
hemoglobin, potassium, and creatinine was performed in less 
than 50% of patients [25]. Even with this limited monitoring, 
which almost certainly led to a marked underascertainment of 
drug-related toxicities, amphotericin B–related adverse events 
were frequently detected, indicating the substantial toxicity of 
amphotericin B deoxycholate. As expected, the main toxicities 
were anemia (median 2-g/dL drop in hemoglobin during treat-
ment), renal impairment, and hypokalemia. Amphotericin B 
doses were frequently missed, with more than half of patients 
missing at least 1 dose. Although we cannot ascertain for certain 
from our data, it is likely that while some missed amphotericin 
doses were intentionally withheld due to drug-related toxici-
ties, the majority were missed due to the logistical challenges of 
administering daily intravenous therapy in an under-resourced 
health care setting. Unlike many African settings, Princess 
Marina Hospital has not had regular stock-outs of amphotericin 
B either during the study period or subsequently.
Importantly, short-term outcomes observed with ampho-
tericin B deoxycholate plus fluconazole 800  mg/d treatment 
under usual care conditions were only marginally better than 
the survival described in prospective cohorts and RCTs from 
sub-Saharan Africa with high-dose (800–1200  mg/d) flu-
conazole monotherapy [26–29], likely reflecting the trade-off 
between more effective fungal clearance with amphotericin B 
deoxycholate [7, 30] and greater risk of severe drug-related tox-
icities and additional risks with extended intravenous therapy 
[9, 31].
The baseline predictors of mortality in this routine care 
cohort—older age, abnormal mental status, raised peripheral 
white blood cell count, hyponatremia, and low CSF white blood 
cell count—have previously been described in prospective 
cohort studies [7]. Seventy-five percent of patients had been 
diagnosed with HIV before admission, and almost half (45%) 
were on ART at the time of admission, reflecting recent shifts 
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Figure  1. Kaplan-Meier survival curves showing the probability of survival following presentation with a first episode of HIV-associated cryptococcal meningitis in 
Botswana. A, Survival for all 236 patients, with vertical dotted lines indicating 2 weeks (26% mortality), 10 weeks (50% mortality), and 12 months (65% mortality). B, Survival 
stratified by antiretroviral therapy (ART) status at presentation. C, Survival stratified by mental status. D, According to number of missed amphotericin B deoxycholate doses.
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in the epidemiology of cryptococcal meningitis [8, 32, 33]. In 
contrast to a previous smaller study from Botswana [34], there 
was no evidence that being on ART at the time of initial pres-
entation with cryptococcal meningitis led to improved out-
comes. Conversely, although there was no significant difference 
in 2-week mortality between ART-experienced and ART-naïve 
patients, 10-week and 1-year outcomes were significantly worse 
in ART-experienced individuals in adjusted analysis. This may 
reflect the fact that many of these individuals were already fail-
ing or defaulting ART at the time of initial presentation and had 
worse adherence and outcomes once re-initiated on ART.
Given the high ongoing burden of HIV-associated crypto-
coccal meningitis in Africa [1, 16] and the extremely poor out-
comes now described with amphotericin B deoxycholate plus 
fluconazole treatment, there is an urgent need to improve access 
to more effective, safe, and easily administered cryptococcal 
treatments in Africa. One potential strategy is shorter-course 
AmB-d treatment courses (7  days) [22], which may provide 
equivalent fungicidal activity to standard 14-day courses 
while avoiding many of the associated toxicities [35, 36]. In 
the recently completed ACTA trial [22], 1 week of AmB-d 
given with flucytosine was a highly effective and well-tolerated 
treatment, leading to lower mortality than standard 2-week 
treatment courses. One-week AmB-d given with fluconazole 
800 mg/d was far less effective, leading to higher mortality than 
standard treatment, suggesting that such a short-course strategy 
is only viable with a more effective oral backbone therapy than 
fluconazole. Compatible with these trial findings, in this routine 
care cohort, missing any amphotericin doses was a strong pre-
dictor of mortality, even when accounting for related dose-lim-
iting toxicities that may have led to the doses being withheld. 
This supports updated guidance recommending that in the 
context of fluconazole as the partner drug, AmB-d treatment 
should be given for a full 14-day course [14], and emphasizes 
the urgent need to establish access to flucytosine in Africa.
Another promising strategy to reduce mortality, currently 
being evaluated in a phase III study (ISRCTN 72509687), is 
administration of single high dose of liposomal amphotericin 
B. Phase II data have shown single 10-mg/kg doses to be safe, 
with similar early fungal clearance compared with 2 weeks of 
standard liposomal amphotericin B dosing [37]. In parallel with 
efforts to develop new improved drug treatment regimens and 
ensure access to these treatments, work is needed to ensure that 
patients who are receiving the currently available amphotericin 
B deoxycholate treatments in low-resource settings receive 
adequate toxicity monitoring and routine therapeutic lumbar 
punctures. These factors are often related to broader health sys-
tem challenges and require addressing complex issues of equip-
ment stock-out, physician training, and health care funding.
Our study has several important limitations, primarily relat-
ing to the retrospective data collection. Botswana’s electronic 
death registry and electronic laboratory records enabled near 
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complete ascertainment of 1-year vital status data and labora-
tory results. However, we were still dependent on retrospective 
medical record review to collate several key clinical variables. 
Paper medical records were missing in a substantial proportion 
of patients, limiting clinical data availability. Patient weights 
were rarely available, precluding any assessment of potential 
weight-based underdosing or overdosing of amphotericin. The 
median weight in the cryptococcal meningitis patients in our 
clinical trials in these settings (IQR) was 52 (45–61) Kg [37], 
with a very small minority over 70 Kg, suggesting that a sin-
gle 50-mg vial should provide a suitable weight-based dose of 
0.7–1 mg/kg in most cases, with a higher probability of over- 
rather than underdosing. Documentation of therapeutic lum-
bar punctures and follow-up CSF opening pressures was poor, 
making a full analysis of the contribution of CSF pressure 
management difficult. Potential drug toxicities not captured 
through laboratory testing, such as thrombophlebitis, vomit-
ing, and infusion reactions, were not routinely recorded; thus 
we can make no inference about their frequency or how often 
they contributed to discontinuation of amphotericin treat-
ment. HIV viral load data were not available for the majority 
of ART-experienced patients at the time of CM presentation. 
In addition, data regarding ART initiation post–cryptococcal 
treatment were not available, precluding any assessment of the 
impact of ART timing on long-term outcome.
In conclusion, through analysis of registry-based data 
and electronic medical records, this study has demonstrated 
the extremely high mortality resulting from HIV-associated 
cryptococcal meningitis in patients treated with standard 
amphotericin B deoxycholate and high-dose fluconazole 
therapy in Africa. Much of this mortality occurs in the first 
months after hospital discharge and would be missed in hos-
pital-based studies. These findings highlight the urgent need 
for effective implementation of cryptococcal prevention 
strategies such as cryptococcal antigen screening, the need 
for new, easy-to-administer, and effective treatment regimens 
for cryptococcal meningitis, and the importance of advocacy 
efforts to ensure that drugs such as flucytosine and liposomal 
amphotericin B, which will form the key components of these 
new treatment regimens, are made accessible and affordable 
in Africa.
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